Table 1.
Clinicopathological characteristics, MYC, hTERT and TP53 expression, and TP53 copies in gastric samples
| Superficial gastritis | Atrophic gastritis | Intestinal metaplasia | |
|---|---|---|---|
|
Gender | |||
| Male [N (%)] |
12 (63.2) |
11 (61.1) |
12 (66.7) |
| Female [N (%)] |
7(36.8) |
7 (38.9) |
6 (33.3) |
|
Alcohol consumption | |||
| Negative [N (%)] |
10 (52.6) |
10 (55.6) |
12 (66.7) |
| Positive [N (%)] |
9 (47.4) |
8 (44.4) |
6 (33.3) |
|
Cigarette smoking | |||
| Negative [N (%)] |
10 (52.6) |
12 (66.7) |
9 (50) |
| Positive* [N (%)] |
9 (47.4) |
6 (33.3) |
9 (50) |
|
H. pylori infection | |||
| Negative [N (%)] |
7 (36.8) |
5 (27.8) |
1 (5.6) |
| Positive [N (%)] |
12 (63.2) |
13 (72.2) |
17 (94.4) |
|
hTERTmRNA expression | |||
| RQ (Mean ± SD) |
1.092 ± 0.61 |
0.821 ± 0.47 |
1.184 ± 0.55 |
|
MYCmRNA expression | |||
| RQ (Mean ± SD) |
0.852 ± 0.51** |
0.873 ± 0.28** |
1.901 ± 0.49 |
|
TP53mRNA expression | |||
| RQ (Mean ± SD) |
0.997 ± 0.59 |
0.847 ± 0.79 |
1.021 ± 0.61 |
|
hTERT immunoreactivity | |||
| Negative [N (%)] |
19 (100) |
18 (100) |
10 (55.6) |
| Positive [N (%)] |
0 (0)** |
0 (0)** |
8 (44.4) |
|
MYC immunoreactivity | |||
| Negative [N (%)] |
19 (100) |
18 (100) |
10 (55.6) |
| Positive [N (%)] |
0 (0)** |
0 (0)** |
8 (44.4) |
|
p53immunoreactivity | |||
| Negative [N (%)] |
19 (100) |
18 (100) |
12 (66.7) |
| Positive [N (%)] |
0 (0)** |
0 (0)** |
6 (33.3) |
|
TP53copies | |||
| 2 copies [N (%)] |
18 (100) |
18 (100) |
15 (83.3) |
| 1 copy [N (%)] | 0 (0) | 0 (0) | 3 (16.7)*** |
RQ: relative quantification.
*Patients smoking one or more cigarettes per day (range 1–20).
**Significantly different from intestinal metaplasia group.
***Gastritis was significantly different from intestinal metaplasia group.